Article published by ASSET, coordinated by Diamyd Medical, advocates for national screening programs in Sweden for early detection of Type 1 DiabetesAn opinion piece article published by members of the ASSET steering group in Göteborgs-Posten, western Sweden’s largest daily morning paper, underscores the need for early detection of Type 1 Diabetes through national screening programs. Each year, approximately 2,000 people, including 1,000 children, are diagnosed with Type 1 Diabetes in Sweden – one of the highest rates worldwide. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a component in the treatments of metabolic diseases. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB. Diamyd Medical AB (publ)Box 7349, SE-103 90 Stockholm, Sweden.

Source: Göteborgs-Posten November 25, 2024 07:38 UTC